Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.55% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTCorMedix Inc.'s latest supported as-filed period reports revenue of $101.9M, 156.5% above the comparable as-filed period; gross margin moved 1965 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.55% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 84.60% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 156.52% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 37.85% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 75.66% · CORE
Level · gp.fundamentals.operating_margin
Raw value 42.10% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 156.5%; Operating margin moved 709 bp lower; Operating income increased 119.6%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 156.5%; Operating margin moved 709 bp lower; Operating income increased 119.6%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Inventory increased 300.5%; Inventory / revenue moved 1361 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Gross margin moved 1965 bp lower; Operating margin moved 709 bp lower.
2 evidence-backed componentsOperating income changed +119.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
CRMD · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-096386SEC ↗4Sep 1, 2026Period Aug 29, 20260001213900-26-096385SEC ↗4Sep 1, 2026Period Aug 29, 20260001213900-26-096383SEC ↗10-QAug 13, 2026Period Jun 30, 20260001410098-26-000056SEC ↗8-KAug 13, 2026Period Aug 13, 20260001410098-26-000054SEC ↗8-KAug 7, 2026Period Aug 7, 20260001410098-26-000044SEC ↗8-KJul 2, 2026Period Jun 29, 20260001410098-26-000040SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 29, 2026Filed Sep 1, 2026 | Hurlburt ElizabethChief Operating Officer | Tax WithholdingDirect | 8,076 | $8 | $67,031 | Form 4 ↗ |
| Aug 29, 2026Filed Sep 1, 2026 | Blum SusanChief Financial Officer | Tax WithholdingDirect | 8,424 | $8 | $69,919 | Form 4 ↗ |
| Feb 4, 2026Filed Feb 6, 2026 | Zelnick Kaufman BethChief Legal Officer | Grant Or AwardDirect | 36,006 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 6.56% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 4.01% · OPTIONAL
Inventory changed +300.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Research & development changed +173.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Gross margin changed -1965 basis points from the comparable as-filed period.
Revenue changed +156.5% from the comparable as-filed period.
Operating margin changed -709 basis points from the comparable as-filed period.
Net income changed +31.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001410098-26-000037